A. Parés

发表

Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis.

A. Castells, Á. Ginés, L. Caballería, 2001 .

Short‐ and long‐term outcome of severe alcohol‐induced hepatitis treated with steroids or enteral nutrition: A multicenter randomized trial

E. Cabré, M. Gassull, M. Papo, 2000, Hepatology.

Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis.

N. Guañabens, P. Peris, F. Pons, 2010, Gastroenterology.

Sclerostin Expression in Bile Ducts of Patients With Chronic Cholestasis May Influence the Bone Disease in Primary Biliary Cirrhosis

S. Ruiz-Gaspà, R. Miquel, N. Guañabens, 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Management of osteoporosis in liver disease.

N. Guañabens, A. Parés, 2011, Clinics and research in hepatology and gastroenterology.

Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development.

K. Boberg, A. Bergquist, E. Schrumpf, 2000, Journal of hepatology.

Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid.

J. Rodés, L. Caballería, A. Parés, 2006, Gastroenterology.

A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.

D. Magrez, K. Kowdley, V. Luketic, 2021, Journal of hepatology.

Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis

J. Rodés, L. Alvarez, N. Guañabens, 2003, American Journal of Gastroenterology.

Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis.

J. Rodés, L. Alvarez, N. Guañabens, 2003 .

Patients with cirrhosis and ascites have false values of bone density

L. Río, F. Pons, N. Guañabens, 2012, Osteoporosis International.

Tuberculosis Is Not a Risk Factor for Primary Biliary Cirrhosis: A Review of the Literature

A. Burroughs, D. Bogdanos, D. Smyk, 2012, Tuberculosis research and treatment.

Antimitochondrial antibodies in patients with chronic hepatitis C virus infection: description of 18 cases and review of the literature

J. Sánchez-Tapias, M. Ramos-Casals, R. Solans, 2005, Journal of viral hepatitis.

Pulmonary involvement in primary biliary cirrhosis.

R. Rodríguez-Roisín, A. Parés, J. Rodés, 1981, Thorax.

Cholangiocarcinoma in Primary Sclerosing Cholangitis: Risk Factors and Clinical Presentation

K. Boberg, A. Bergquist, E. Schrumpf, 2002, Scandinavian journal of gastroenterology.

Kinetic Analyses of Antiviral Suppression by NS5A Inhibitors Reveal Early and Potent Inhibition of Viral Assembly and Release of Infectious Virus The rs2294918 K434E PNPLA3 Polymorphism is associated with Nonalcoholic Fatty Liver and Steatohepatitis

J. Talwalkar, A. Burroughs, F. Nevens, 2013 .

Management of primary biliary cirrhosis: osteoporosis

A. Parés, 1998 .

The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts

A. Enjuanes, S. Ruiz-Gaspà, N. Guañabens, 2010, Endocrine.

Vertebral fractures and osteopenia in chronic alcoholic patients

J. Rodés, L. Río, F. Pons, 1995, Calcified Tissue International.

High osteoprotegerin serum levels in primary biliary cirrhosis are associated with disease severity but not with the mRNA gene expression in liver tissue

A. Enjuanes, N. Guañabens, P. Peris, 2009, Journal of Bone and Mineral Metabolism.

Bone Disease in Patients with Cirrhosis

N. Guañabens, A. Parés, 2015 .

Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment.

N. Guañabens, A. Parés, 2008, Clinics in liver disease.

N. Guañabens, P. Peris, A. Parés, 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Thyroid Dysfunction in Primary Biliary Cholangitis: A Comparative Study at Two European Centers

A. Floreani, S. Cocchio, V. Baldo, 2017, The American Journal of Gastroenterology.

Albumin dialysis improves hepatic encephalopathy and decreases circulating phenolic aromatic amino acids in patients with alcoholic hepatitis and severe liver failure

R. Deulofeu, J. Caballería, A. Parés, 2009, Critical care.

S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial.

J. Rodés, J. Caballería, J. Mato, 1999, Journal of hepatology.

Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial.

J. Panés, J. Caballería, A. Parés, 1998, Journal of hepatology.

Enhanced liver fibrosis test predicts transplant‐free survival in primary sclerosing cholangitis, a multi‐centre study

T. Karlsen, K. Boberg, O. Gilja, 2017, Liver international : official journal of the International Association for the Study of the Liver.

A randomized placebo controlled trial of vitamin E for alcoholic hepatitis.

J. Caballería, E. Mezey, J. Potter, 2004, Journal of hepatology.

225 A randomized placebo controlled trial of vitamin E in alcoholic hepatitis

J. Caballería, E. Mezey, J. Potter, 2003 .

Effects of S-adenosylmethionine on lipid peroxidation and liver fibrogenesis in carbon tetrachloride-induced cirrhosis.

M. Pajares, J. Rodés, G. Varela, 1996, Journal of hepatology.

Comparative study of aminoglycoside nephrotoxicity in normal rats and rats with experimental cirrhosis

V. Arroyo, J. Rodés, J. Camps, 1988, Hepatology.

Enhanced DNA Binding and Activation of Transcription Factors NF-κB and AP-1 by Acetaldehyde in HEPG2 Cells*

J. Fernandez-Checa, J. Lluis, J. Caballería, 2000, The Journal of Biological Chemistry.

Differential role of ethanol and acetaldehyde in the induction of oxidative stress in HEP G2 cells: Effect on transcription factors AP‐1 and NF‐κB

A. Colell, J. Fernandez-Checa, J. Caballería, 1999 .

S‐adenosylmethionine treatment prevents carbon tetrachloride—induced S‐adenosylmethionine synthetase inactivation and attenuates liver injury

M. Pajares, F. Corrales, J. Mato, 1992, Hepatology.

Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis

J. Rodés, R. Deulofeu, J. Caballería, 1996, Hepatology.

Determinants of ethanol and acetaldehyde metabolism in chronic alcoholics.

M. Navasa, J. Panés, X. Parés, 1993, Alcoholism, clinical and experimental research.

Influence of liver disease on hepatic alcohol and aldehyde dehydrogenases.

J. Panés, J. Farrés, X. Parés, 1989, Gastroenterology.

Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease

Mariza de Andrade, Andre Franke, Wolfgang Lieb, 2016, Nature Genetics.

Expected developments in hepatology.

J. Bruix, J. Llovet, X. Forns, 2002, Best practice & research. Clinical gastroenterology.

Effects of prolonged ethanol intake and malnutrition on rat pancreas.

J. Bombí, J. Caballería, S. Imperial, 1996, Gut.

Noninvasive Prediction of Outcomes in Autoimmune Hepatitis–Related Cirrhosis

C. Fernández-Rodríguez, M. Londoño, M. García-Retortillo, 2022, Hepatology communications.

Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: Comparative analysis from two centers

A. Floreani, F. Farinati, L. Caballería, 2009, Hepatology.

Liver and bone.

N. Guañabens, A. Parés, 2010, Archives of biochemistry and biophysics.

Validity of self-reported alcohol consumption in the emergency room: data from the United States, Mexico and Spain.

C. Cherpitel, A. Parés, J. Rodés, 1992, Journal of studies on alcohol.

University of Birmingham Risk Stratification in autoimmune cholestatic liver diseases

P. Trivedi, G. Hirschfield, C. Corpechot, 2015 .

Histone deacetylase 4 promotes cholestatic liver injury in the absence of prohibitin‐1

Shelly C. Lu, F. Lopitz-Otsoa, M. Martínez-Chantar, 2015, Hepatology.

Bilirubin increases viability and decreases osteoclast apoptosis contributing to osteoporosis in advanced liver diseases.

N. Guañabens, P. Peris, A. Combalía, 2022, Bone.

Bone mass improves in alcoholics after 2 years of abstinence

N. Guañabens, P. Peris, J. Caballería, 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis

D. Vergani, J. Rodés, D. Bogdanos, 2005, Gut.

Primary biliary cirrhosis associated with HLA-DRw3.

A. Parés, J. Rodés, M. Bruguera, 2008, Tissue antigens.

Liver transplant‐free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid

F. Nevens, K. Lindor, C. Ponsioen, 2022, Alimentary pharmacology & therapeutics.

Artificial liver support in patients with liver failure: a modified DELPHI consensus of international experts

S. Jaber, T. Hassanein, D. Samuel, 2022, Intensive Care Medicine.

Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis

A. Floreani, G. Hirschfield, R. Pencek, 2020, JHEP reports : innovation in hepatology.

Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis

M. Shiffman, G. Hirschfield, L. Macconell, 2020, Liver international : official journal of the International Association for the Study of the Liver.

Primary biliary cholangitis.

A. Parés, 2018, Medicina clinica.

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis

R. Chapman, K. Kowdley, L. Adorini, 2018, Hepatology.

Treatment of primary biliary cirrhosis: Is there more to offer than ursodeoxycholic acid?

A. Parés, 2014, Clinical liver disease.

Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid

S. Lens, A. Parés, M. Bruguera, 2014, Liver international : official journal of the International Association for the Study of the Liver.

Genetic polymorphism of liver alcohol dehydrogenase in Spanish subjects: significance of alcohol consumption and liver disease.

J. Panés, J. Farrés, X. Parés, 1994, Alcohol and alcoholism.

Prevalence and mechanisms of hyperhomocysteinemia in chronic alcoholics.

J. Rodés, J. Lluis, R. Deulofeu, 2005, Alcoholism, clinical and experimental research.

Treatment of bone disorders in liver disease.

N. Guañabens, A. Parés, 2006, Journal of hepatology.

Cyclosporin A increases the biochemical markers of bone remodeling in primary biliary cirrhosis.

J. Rodés, N. Guañabens, A. Parés, 1994, Journal of hepatology.

Hepatotoxicity associated with glucosamine and chondroitin sulfate in patients with chronic liver disease.

A. Parés, M. Bruguera, C. Cerda, 2013, World journal of gastroenterology.

Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis.

V. de Lédinghen, F. Carrat, F. Nevens, 2022, Journal of hepatology.

Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study

R. Andrade, M. Vergara, M. Diago, 2021, The American journal of gastroenterology.

Colangitis biliar primaria

A. Parés, 2016, Medicina Clínica.

Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response

A. Parés, Anna Reig, P. Sesé, 2018, The American Journal of Gastroenterology.

Advances in treatment options for patients with primary biliary cholangitis

A. Parés, 2017 .

Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis

N. Guañabens, P. Peris, A. Parés, 2013, Hepatology.

Long-term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis.

U. Iloeje, L. Terracciano, P. Bedossa, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

28 AN INTERNATIONAL STUDY EVALUATING THE FARNESOID X RECEPTOR AGONIST OBETICHOLIC ACID AS MONOTHERAPY IN PBC

R. Chapman, A. Burroughs, K. Kowdley, 2011 .

Lithocholic acid downregulates vitamin D effects in human osteoblasts

A. Enjuanes, S. Ruiz-Gaspà, N. Guañabens, 2010, European journal of clinical investigation.

Quantitative measurement of fibrosis in pancreatic tissue. Evaluation of a colorimetric method.

J. Camps, J. Caballería, A. Parés, 1991, International journal of pancreatology : official journal of the International Association of Pancreatology.

Antibodies to mycobacterial 65‐kD heat shock protein cross‐react with the main mitochondrial antigens in patients with primary biliary cirrhosis

J. Vila, A. Parés, J. Rodés, 1997, European journal of clinical investigation.

Promoter hypermethylation of the AE2/SLC4A2 gene in PBC

J. Prieto, A. Parés, I. Hervías, 2019, JHEP reports.

Hepatic stellate cell nomenclature.

Desmet, S. French, D. Brenner, 1996, Hepatology.

Alcoholic foamy degeneration in Spain. Prevalence and clinico-pathological features.

J. Caballería, A. Parés, J. Rodés, 2008, Liver.

Changing Nomenclature for PBC: From 'Cirrhosis' to 'Cholangitis'.

I. Mackay, R. Gish, David E. J. Jones, 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Effects of long-term rifampicin administration in primary biliary cirrhosis.

A. Parés, J. Rodés, C. Piera, 1992, Gastroenterology.

Hepatitis C virus antibodies in chronic alcoholic patients: Association with severity of liver injury

J. Caballería, L. Caballería, A. Parés, 1990, Hepatology.

Hepatitis C virus infection in patients with nonalcoholic chronic liver disease.

J. Bruix, J. Sánchez-Tapias, X. Calvet, 1990, Annals of internal medicine.

The Prevalence of Anti-Hexokinase-1 and Anti-Kelch-Like 12 Peptide Antibodies in Patients With Primary Biliary Cholangitis Is Similar in Europe and North America: A Large International, Multi-Center Study

M. Fritzler, M. Swain, M. Mahler, 2019, Front. Immunol..

Drinking patterns and problems: a comparison of emergency room populations in the United States and Spain.

J. Rodés, C. Cherpitel, A. Parés, 1991, Drug and alcohol dependence.

Zinc administration improves gastric alcohol dehydrogenase activity and first-pass metabolism of ethanol in alcohol-fed rats.

J. Rodés, R. Deulofeu, J. Caballería, 1997, Alcoholism, clinical and experimental research.

Sodium fluoride prevents bone loss in primary biliary cirrhosis.

J. Rodés, N. Guañabens, A. Parés, 1992, Journal of hepatology.

Higher seroprevalence of hepatitis E virus in autoimmune hepatitis: Role of false‐positive antibodies

X. Forns, M. Londoño, S. Lens, 2019, Liver international : official journal of the International Association for the Study of the Liver.

Acetaldehyde activates the promoter of the mouse α2(I) collagen gene

E. Mezey, J. Potter, A. Parés, 1994 .

Characterization and differentiation of autoimmune versus viral liver involvement in patients with Sjögren's syndrome.

X. Forns, J. Sánchez-Tapias, J. Rodés, 2006, The Journal of rheumatology.

Drinking in the injury event: a comparison of emergency room populations in the United States, Mexico, and Spain.

C. Cherpitel, A. Parés, J. Rodés, 1993, The International journal of the addictions.

[Alcohol consumption and accidents in Barcelona. Epidemiologic study].

J. Caballería, A. Parés, J. Rodés, 1988, Medicina clinica.

Alcohol and viral hepatitis: interactions and management

J. Caballería, A. Parés, 2002 .

Are hepatitis C virus antibodies involved in chronic liver diseases other than non‐A, non‐B hepatitis?

J. Caballería, L. Caballería, A. Parés, 1991, Hepatology.

S-adenosylmethionine prevents hepatic tocopherol depletion in carbon tetrachloride-injured rats.

G. Varela-Moreiras, J. Rodés, R. Deulofeu, 2000, Clinical science.

Serum procollagen type III peptide as a marker of hepatic fibrogenesis in alcoholic hepatitis.

W. Jiménez, J. Caballería, A. Parés, 1986, Gastroenterology.

anagement of osteoporosis in liver disease

A. Parés, úria Guañabens, 2011 .

Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis.

J. Rodés, N. Guañabens, P. Peris, 2005, Journal of hepatology.

High Bilirubin Levels Interfere with Serum Tartrate-Resistant Acid Phosphatase Determination: Relevance as a Marker of Bone Resorption in Jaundiced Patients

N. Guañabens, P. Peris, A. Ballesta, 1999, Calcified Tissue International.

Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years.

J. Rodés, F. Pons, N. Guañabens, 1997, Gastroenterology.

Factors influencing the development of metabolic bone disease in primary biliary cirrhosis.

F. Rivera, N. Guañabens, A. Parés, 1990, The American journal of gastroenterology.

Antibodies against the COOH-terminal region of E. coli ClpP protease in patients with primary biliary cirrhosis.

J. Rodés, P. Arizti, A. Parés, 2000, Journal of hepatology.

Cross-reactivity of anti-Mycobacterium gordonae antibodies with the major mitochondrial autoantigens in primary biliary cirrhosis.

J. Vila, A. Parés, J. Rodés, 1994, Journal of hepatology.

[Primary biliary cirrhosis, a multisystemic disease?].

A. Parés, J. Rodés, 1986, Medicina clinica.

Reduced spinal and femoral bone mass and deranged bone mineral metabolism in chronic alcoholics.

J. Rodés, J. Caballería, F. Pons, 1992, Alcohol and alcoholism.

Novel Anti-Hexokinase 1 Antibodies Are Associated With Poor Prognosis in Patients With Primary Biliary Cholangitis.

M. Mahler, M. Romera, S. Ruiz-Gaspà, 2020, The American journal of gastroenterology.

New ELISA for detecting primary biliary cirrhosis-specific antimitochondrial antibodies.

D. Vergani, D. Bogdanos, M. Mytilinaiou, 2009, Clinical chemistry.

Anti‐gp210 antibody mirrors disease severity in primary biliary cirrhosis

D. Vergani, J. Rodés, D. Bogdanos, 2007, Hepatology.

Primary Biliary Cirrhosis Specific Antinuclear Antibodies in Patients from Spain

D. Vergani, J. Rodés, A. Parés, 2004, American Journal of Gastroenterology.

Autoantibodies against nuclear envelope‐associated proteins in primary biliary cirrhosis

M. Plana, T. Gallart, L. Borche, 1988, Hepatology.

Fibrogenic and collagenolytic activity in carbon-tetrachloride-injured rats: beneficial effects of zinc administration.

J. Rodés, R. Deulofeu, J. Camps, 1994, Journal of hepatology.

Bilirubin and bile acids in osteocytes and bone tissue. Potential role in the cholestatic‐induced osteoporosis

S. Ruiz-Gaspà, N. Guañabens, P. Peris, 2020, Liver international : official journal of the International Association for the Study of the Liver.

Bile acids and bilirubin effects on osteoblastic gene profile. Implications in the pathogenesis of osteoporosis in liver diseases.

S. Ruiz-Gaspà, N. Guañabens, P. Peris, 2020, Gene.

Bile acids and bilirubin effects on osteoblastic gene profile. Implications in the pathogenesis of osteoporosis in liver diseases

S. Ruiz-Gaspà, N. Guañabens, P. Peris, 2019, bioRxiv.

Ursodeoxycholic acid decreases bilirubin‐induced osteoblast apoptosis

S. Ruiz-Gaspà, N. Guañabens, P. Peris, 2014, European journal of clinical investigation.

Ursodeoxycholic acid increases differentiation and mineralization and neutralizes the damaging effects of bilirubin on osteoblastic cells

S. Ruiz-Gaspà, N. Guañabens, P. Peris, 2013, Liver international : official journal of the International Association for the Study of the Liver.

Effects of bilirubin and sera from jaundiced patients on osteoblasts: Contribution to the development of osteoporosis in liver diseases

A. Enjuanes, S. Ruiz-Gaspà, N. Guañabens, 2011, Hepatology.

Gene polymorphisms as predictors of decreased bone mineral density and osteoporosis in primary biliary cirrhosis

J. Rodés, N. Guañabens, A. Parés, 2005, European journal of gastroenterology & hepatology.

Collagen type Iα1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis

F. Rivera, N. Guañabens, P. Peris, 2001 .

Serum Immunological Profile in Patients with Chronic Autoimmune Cholestasis

R. Andrade, M. Diago, J. Crespo, 2004, The American Journal of Gastroenterology.

Liver diseases associated with autoantibodies directed to nuclear envelope components

M. Plana, T. Gallart, D. Dhumeaux, 1989, Hepatology.

Mycobacteria--related to the aetiopathogenesis of primary biliary cirrhosis?

J. Vila, A. Parés, J. Rodés, 1996, Journal of hepatology.

Silymarin: A Review of its Clinical Properties in the Management of Hepatic Disorders

H. Tilg, D. Schuppan, P. Ferenci, 2001 .

Esophageal dysfunction in primary biliary cirrhosis.

J. Bruix, A. Parés, J. Rodés, 1988, Journal of hepatology.

Extracorporeal liver support in severe alcoholic hepatitis.

A. Parés, A. Mas, 2014, World journal of gastroenterology.

Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial

U. Beuers, R. Elferink, K. Zwinderman, 2017, Trials.

Extracorporeal Albumin Dialysis: A Procedure for Prolonged Relief of Intractable Pruritus in Patients with Primary Biliary Cirrhosis

J. Rodés, L. Caballería, A. Parés, 2004, American Journal of Gastroenterology.

University of Birmingham Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis

A. Burroughs, F. Nevens, K. Lindor, 2014 .

Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double blind, randomized, placebo-controlled trial.

N. Mostafavi, C. Ponsioen, J. Drenth, 2020, Gastroenterology.

Bone Health in Patients with Autoimmune Liver Diseases

N. Guañabens, A. Parés, 2020 .

Renal tubular acidosis in primary biliary cirrhosis.

A. Rimola, A. Parés, J. Rodés, 1981, Gastroenterology.

Serum Amino‐Terminal Propeptide of Type III Procollagen Levels in Chronic Pancreatitis

J. Caballería, J. Caballería, A. Parés, 1996, Pancreas.

Influence of zinc intake on hepatic lipid peroxidation and metallothioneins in alcoholic rats: relationship to collagen synthesis.

J. Joven, J. Rodés, J. Folch, 1995, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition.

Influence of dietary zinc on hepatic collagen and prolyl hydroxylase activity in alcoholic rats.

J. Rodés, R. Deulofeu, J. Caballería, 1990, Hepatology.

The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality

M. Manns, V. Mazzaferro, M. Buti, 2021, The Lancet.

Alcohol dehydrogenase from human stomach: variability in normal mucosa and effect of age, gender, ADH3 phenotype and gastric region.

X. Parés, J. Enriquez, A. Parés, 1994, Alcohol and alcoholism.

Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult‐to‐treat primary biliary cholangitis

T. Berg, F. Carrat, P. Potier, 2021, Alimentary pharmacology & therapeutics.

Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase.

F. Nevens, K. Lindor, C. Ponsioen, 2020, The American journal of gastroenterology.

Factors Associated With Progression and Outcomes of Early-stage Primary Biliary Cholangitis.

F. Nevens, K. Lindor, C. Ponsioen, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response

F. Nevens, K. Lindor, C. Ponsioen, 2019, Alimentary pharmacology & therapeutics.

Mo1471 – Three Years of Obeticholic Acid Therapy Results in Histological Improvements in Patients with Primary Biliary Cholangitis: Further Analysis of the Poise Biopsy Substudy

L. Terracciano, A. Floreani, P. Bedossa, 2019, Gastroenterology.

Milder disease stage in patients with primary biliary cholangitis over a 44‐year period: A changing natural history

N. LaRusso, F. Nevens, K. Lindor, 2018, Hepatology.

University of Birmingham Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy

A. Burroughs, F. Nevens, K. Lindor, 2022 .

Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study.

A. Burroughs, F. Nevens, K. Lindor, 2014, Gastroenterology.

Relationship between hepatic lipid peroxidation and fibrogenesis in carbon tetrachloride-treated rats: effect of zinc administration.

J. Joven, J. Rodés, L. Masana, 1992, Clinical science.

AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Simplified Criteria for the Diagnosis of Autoimmune Hepatitis

K. Boberg, P. Galle, H. Dienes, 2008 .

COMPARISON OF RIFAMPICIN WITH PHENOBARBITONE FOR TREATMENT OF PRURITUS IN BILIARY CIRRHOSIS

A. Parés, J. Rodés, C. Piera, 1989, The Lancet.

Acute thallium poisoning: an evaluation of different forms of treatment.

J. Millá, S. Nogué, A. Parés, 1982, Journal of toxicology. Clinical toxicology.

Levels of Alkaline Phosphatase and Bilirubin are Surrogate Endpoints of Outcomes of Patients with Primary Biliary Cirrhosis – an International Follow-up Study Short title : Alkaline phosphatase and bilirubin as surrogate endpoints in PBC

A. Burroughs, F. Nevens, K. Lindor, 2014 .

[Natural history of primary biliary cirrhosis].

A. Parés, 2008, Gastroenterologia y hepatologia.

Lymphocytotoxic antibodies in primary biliary cirrhosis

J. Caballería, A. Parés, J. Rodés, 1985, Digestive Diseases and Sciences.

Natural history of primary biliary cirrhosis.

J. Rodés, A. Parés, 2003, Clinics in liver disease.

Role for mycobacterial infection in pathogenesis of primary biliary cirrhosis?

Y. Zen, D. Bogdanos, D. Smyk, 2012, World journal of gastroenterology.

Primary Biliary Cirrhosis and Sclerosing Cholangitis

A. Parés, J. Rodés, J. Rodés, 1992 .

EASL Clinical Practice Guidelines: management of cholestatic liver diseases.

F. Lammert, K. Boberg, R. Chapman, 2009, Journal of hepatology.

EASL Clinical Practice Guidelines on nutrition in chronic liver disease.

M. Plauth, L. Genton, M. Merli, 2019, Journal of hepatology.

Guidelines EASL Clinical Practice Guidelines on nutrition in chronic liver disease q European Association for the Study of the Liver * Summary

M. Plauth, L. Genton, S. Montagnese, 2018 .

Analysis of factors predicting early seroconversion to anti-HBe in HBeAg-positive chronic hepatitis B.

J. Rodés, A. Parés, A. Mas, 1988, Journal of hepatology.

Osteoporosis in chronic liver disease

N. Guañabens, A. Parés, 2018, Liver international : official journal of the International Association for the Study of the Liver.

Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.

F. Carrat, F. Nevens, F. Rauchfuß, 2020, Journal of hepatology.

Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival.

F. Nevens, A. Floreani, J. Dumortier, 2019, Gastroenterology.

Hepatitis G virus infection in chronic liver disease

J. Bruix, X. Forns, S. Ampurdanés, 1998, Gut.

Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second‐line Therapy for Patients With Autoimmune Hepatitis

T. Berg, T. Schiano, A. Montano‐Loza, 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis

Judy H. Cho, Nadezhda T. Doncheva, O. Andreassen, 2013, Nature Genetics.

Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial

J. Rodés, L. Rodrigo, D. Rodríguez-Martínez, 2000 .

Epidemiology of primary sclerosing cholangitis in Spain

A. Parés, J. Rodés, M. Miras, 1994 .

Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute‐on‐chronic liver failure: The RELIEF trial

Antonio Gasbarrini, Rajiv Jalan, Faouzi Saliba, 2013, Hepatology.

Measurement of fibrosis in needle liver biopsies: Evaluation of a colorimetric method

W. Jiménez, M. Rojkind, J. Caballería, 1985, Hepatology.

Serum paraoxonase-1 in chronic alcoholics: relationship with liver disease.

J. Joven, R. Deulofeu, J. Camps, 2007, Clinical biochemistry.

Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis.

F. Nevens, K. Lindor, A. Floreani, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage.

J. Caballería, J. Caballería, A. Parés, 1986, Journal of hepatology.

O5 PRIMARY SCLEROSING CHOLANGITIS FROM A GLOBAL PERSPECTIVE – A MULTICENTER, RETROSPECTIVE, OBSERVATIONAL STUDY OF THE INTERNATIONAL PSC STUDY GROUP

M. Manns, C. Strassburg, T. Karlsen, 2014 .

Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.

K. Lindor, K. Kowdley, M. Trauner, 2015, Gastroenterology.

Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis

F. Nevens, K. Lindor, C. Ponsioen, 2019, Gut.

Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group.

M. Manns, M. H. Jørgensen, G. Mieli-Vergani, 2022, Journal of hepatology.

The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts

A. Enjuanes, S. Ruiz-Gaspà, N. Guañabens, 2009, Endocrine.

Disulfiram-induced hepatitis. Report of four cases and review of the literature.

X. Forns, J. Caballería, A. Parés, 1994, Journal of hepatology.

Sex Differences Associated with Primary Biliary Cirrhosis

A. Burroughs, D. Bogdanos, D. Smyk, 2012, Clinical & developmental immunology.

Urine ethanol assessment: a helpful method for controlling abstinence in alcoholic liver disease.

J. Camps, J. Caballería, A. Parés, 1988, Alcohol and alcoholism.

Cyanamide hepatotoxicity. Incidence and clinico-pathological features.

A. Parés, J. Rodés, M. Bruguera, 2008, Liver.

Treatment of primary biliary cirrhosis.

A. Parés, J. Rodés, J. Rodés, 1999, Minerva gastroenterologica e dietologica.

Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.

F. Nevens, K. Lindor, C. Ponsioen, 2019, Journal of hepatology.

HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations.

K. Boberg, E. Schrumpf, E. Thorsby, 1999, Tissue antigens.

The HLA-DR3,DQ2 heterozygous genotype is associated with an accelerated progression of primary sclerosing cholangitis.

K. Boberg, E. Schrumpf, R. Chapman, 2001, Scandinavian journal of gastroenterology.

TRAIL-producing NK cells contribute to liver injury and related fibrogenesis in the context of GNMT deficiency

Shelly C. Lu, J. Mato, A. Lahoz, 2014, Laboratory Investigation.

Extrahepatic Malignancies in Primary Biliary Cirrhosis: A Comparative Study at Two European Centers

A. Floreani, K. Harada, M. Gershwin, 2015, Clinical Reviews in Allergy & Immunology.

Effects of long-term rifampicin administration in primary biliary cirrhosis

A. Parés, J. Rodés, C. Piera, 1992 .

Proteomic Analysis of Polypeptides Captured from Blood during Extracorporeal Albumin Dialysis in Patients with Cholestasis and Resistant Pruritus

M. Gay, M. Carrascal, J. Abian, 2011, PloS one.

Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers.

A. Parés, M. Herrera, A. Mas, 2010, Journal of hepatology.

Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis.

M. Manns, C. Strassburg, T. Karlsen, 2017, Gastroenterology.

Suppression of a broad spectrum of liver autoimmune pathologies by single peptide-MHC-based nanomedicines

Yang Yang, P. Santamaria, C. S. Umeshappa, 2019, Nature Communications.

Therapy of Primary Biliary Cirrhosis: Novel Approaches for Patients with Suboptimal Response to Ursodeoxycholic Acid

A. Parés, 2015, Digestive Diseases.

Influence of dietary zinc on hepatic collagen and prolyl hydroxylase activity in alcoholic rats

R. Deulofeu, J. Caballería, A. Parés, 1992, Hepatology.

Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation.

Maciej K. Janik, M. Manns, V. Ronca, 2022, Journal of hepatology.

Old and Novel Therapies for Primary Biliary Cirrhosis

A. Parés, 2014, Seminars in Liver Disease.

Disease-specific cross-reactivity between mimicking peptides of heat shock protein of Mycobacterium gordonae and dominant epitope of E2 subunit of pyruvate dehydrogenase is common in Spanish but not British patients with primary biliary cirrhosis.

D. Vergani, A. Burroughs, H. Baum, 2004, Journal of autoimmunity.

Enteroendocrine cells are a potential source of serum autotaxin in men.

P. Bosma, U. Beuers, R. O. Oude Elferink, 2016, Biochimica et biophysica acta.

Synthesis and degradation of collagen in pancreatic fibrogenesis.

J. Caballería, A. Parés, L. Fernández‐Cruz, 1999, Pancreas.

Greater Transplant-free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls.

F. Nevens, K. Lindor, A. Floreani, 2022, Gastroenterology.

Portal hypertension in primary biliary cirrhosis. Relationship with histological features.

M. Navasa, J. Rodés, J. Caballería, 1987, Journal of hepatology.

Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'.

I. Mackay, R. Gish, David E. J. Jones, 2015, Journal of hepatology.

Effect of parenteral amino acid supplementation on short‐term and long‐term outcomes in severe alcoholic hepatitis: A randomized controlled trial

J. Caballería, H. Herlong, E. Mezey, 1991, Hepatology.

AUTOIMMUNE , CHOLESTATIC AND BILIARY DISEASE Enhanced Liver Fibrosis Score Predicts Transplant-Free Survival in Primary Sclerosing Cholangitis

F. Lund-Johansen, T. Karlsen, K. Boberg, 2015 .

Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis.

K. Lindor, O. Chazouilleres, R. Poupon, 2003, Journal of hepatology.

Role of Zinc in the Process of Pancreatic Fibrosis in Chronic Alcoholic Pancreatitis

J. Caballería, A. Parés, L. Fernández‐Cruz, 1994, Pancreas.

Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’

David C. Jones, I. Mackay, R. Gish, 2015, Gut.

Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study

Andrew K Burroughs, Pietro Invernizzi, Frederik Nevens, 2015, Gut.

Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis

M. Manns, M. Silverberg, W. Lieb, 2017, Gut.

Characterization of peptides and proteins in commercial HSA solutions

M. Gay, M. Carrascal, J. Abian, 2010, Proteomics.

Primary biliary cholangitis in Spain. Results of a Delphi study of epidemiology, diagnosis, follow-up and treatment.

R. Andrade, J. Crespo, A. Albillos, 2018, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

Excellent long-term survival in patients with primary biliary cirrhosis treated with ursodeoxycholic acid

A. Parés, 2009 .

874 INCIDENCE AND RISK FACTORS FOR HEPATOCELLULAR CARCINOMA IN PRIMARY BILIARY CIRRHOSIS

L. Caballería, A. Parés, M. Bruguera, 2008 .

123 PRESENTATION AND NATURAL HISTORY OF PRIMARY BILIARY CIRRHOSIS IN SPAIN: EXPERIENCE OVER 35 YEARS

A. Parés, 2008 .

Novel Treatment Strategies for Primary Biliary Cholangitis

A. Parés, 2017, Seminars in Liver Disease.

LIVER Ef fi cacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid

Eld, K. Lindor, K. Kowdley, 2015 .

Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis.

F. Nevens, K. Lindor, C. Ponsioen, 2019, Clinical Gastroenterology and Hepatology.

Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome

F. Nevens, K. Lindor, C. Ponsioen, 2018, The American Journal of Gastroenterology.

A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis

F. Nevens, K. Lindor, A. Floreani, 2021, The American journal of gastroenterology.

A placebo-controlled randomised trial of budesonide for primary biliary cholangitis following an insufficient response to UDCA.

M. Manns, A. Bergquist, U. Spengler, 2020, Journal of hepatology.

Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver.

L. Rodrigo, D. Rodríguez-Martínez, A. Parés, 2000, Journal of hepatology.

Quality of life in patients with primary biliary cholangitis: A cross-geographical comparison

V. Ronca, L. Jopson, A. Tanaka, 2021, Journal of translational autoimmunity.

Suppression of a broad spectrum of liver autoimmune pathologies by single peptide-MHC-based nanomedicines

Yang Yang, P. Santamaria, C. S. Umeshappa, 2019, Nature Communications.

Bezafibrate Alleviates Pruritus and Decreases Specific Circulating Metabolites in Patients with Primary Biliary Cholangitis

R. Mayo, M. Pérez-Cormenzana, A. Castro, 2016 .

Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western Europe

F. Nevens, K. Lindor, C. Ponsioen, 2022, European journal of gastroenterology & hepatology.

2 FARNESOID-X RECEPTOR AGONISTS: A NEW CLASS OF DRUGS FOR THE TREATMENT OF PBC? AN INTERNATIONAL STUDY EVALUATING THE ADDITION OF INT-747 TO URSODEOXYCHOLIC ACID

K. Lindor, K. Kowdley, M. Trauner, 2010 .

Long-term ursodeoxycholic acid treatment delays progression of mild primary biliary cirrhosis

J. Rodés, L. Caballería, A. Parés, 2001 .

Factors influencing histological progression of early primary biliary cirrhosis. Effect of ursodeoxycholic acid

J. Rodés, L. Caballería, A. Parés, 2001 .

Ursodeoxycholic Acid Treatment–Induced GLOBE Score Changes Are Associated With Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis

F. Nevens, K. Lindor, C. Ponsioen, 2022, The American journal of gastroenterology.

Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase.

F. Nevens, K. Lindor, C. Ponsioen, 2020, The American journal of gastroenterology.

Results of a randomised controlled trial of budesonide add-on therapy in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid

M. Manns, A. Bergquist, U. Spengler, 2018 .

Changing nomenclature for PBC: From ‘cirrhosis’ to ‘cholangitis’

David C. Jones, I. Mackay, R. Gish, 2015, Hepatology.

Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus–related cirrhosis

A. Castells, L. Caballería, A. Parés, 2001, American Journal of Gastroenterology.

Bilirubin is predictive of transplant-free survival even within the normal range in primary biliary cholangitis patients

N. LaRusso, F. Nevens, K. Lindor, 2017 .

An appealing new agent for treating cholestatic pruritus

A. Parés, 2017, The Lancet.

Ursodeoxycholic acid treatment is associated with prolonged transplant-free survival in primary biliary cholangitis – even in patients without biochemical improvements

F. Nevens, K. Lindor, C. Ponsioen, 2018 .

Comparative effects of second-line therapy with obeticholic acid or fibrates in primary biliary cholangitis patients

R. Andrade, M. Diago, E. Fábrega, 2020, Journal of Hepatology.

[Epidemiology of primary biliary cirrhosis in Cataluna].

J. Guàrdia, I. Seres, A. Parés, 1984, Medicina clinica.

LBO-02-Elafibranor, a peroxisome proliferator-activted receptor alpha and delta agonist demonstrates favourable efficacy and safety in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid treatment

D. Magrez, K. Kowdley, V. Luketic, 2019, Journal of Hepatology.

Simplified care-pathway selection for nonspecialist practice: the GLOBAL Primary Biliary Cholangitis Study Group Age, Bilirubin, Alkaline phosphatase risk assessment tool

F. Nevens, K. Lindor, C. Ponsioen, 2020, European journal of gastroenterology & hepatology.

Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists

P. Trivedi, G. Hirschfield, C. Corpechot, 2015, Hepatology.

Simplified Diagnostic Criteria for Autoimmune Hepatitis

K. Boberg, P. Galle, H. Dienes, 2006 .

Alendronate versus etidronate for osteopenic patients with primary biliary cirrhosis: results after two years of treatment

J. Rodés, F. Pons, N. Guañabens, 2001 .

P373 SERUM METABOLOMIC PROFILING IN PATIENTS WITH CHOLESTATIC PRURITUS. EFFECTS OF ALBUMIN DIALYSIS

R. Mayo, M. Pérez-Cormenzana, A. Castro, 2014 .

Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience.

O. Chazouilleres, C. Corpechot, R. Poupon, 2018, Clinics and research in hepatology and gastroenterology.

Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver.

J. Rodés, A. Parés, M. Miras, 1994, Journal of hepatology.

Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial

J. Panés, J. Caballería, A. Parés, 1998 .

Carbohydrate-deficient transferrin as a marker of alcohol consumption in male patients with liver disease.

J. Rodés, R. Deulofeu, J. Caballería, 1997, Alcoholism, clinical and experimental research.

Primary biliary cholangitis and bone disease.

N. Guañabens, A. Parés, 2018, Best practice & research. Clinical gastroenterology.

Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebo-control trial. Spanish Group for the Study of Alcoholic Fatty Liver.

J. Rodés, J. Caballería, L. Rodrigo, 1998, Journal of hepatology.

Pulmonary involvement inprimary biliary cirrhosis

R. Rodríguez-Roisín, A. Parés, C. Picado, 1981 .

Presentation and Outcomes of Pregnancy in Patients With Autoimmune Hepatitis

M. Londoño, E. Fábrega, M. García-Retortillo, 2019 .

FRAXA premutation associated with premature ovarian failure.

A. Vianna-Morgante, A. Parés, S. Costa, 1996, American journal of medical genetics.

Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one‐year non‐responders and predicts survival

F. Nevens, K. Lindor, C. Ponsioen, 2023, Liver international : official journal of the International Association for the Study of the Liver.

OP02 The first new monotherapy therapeutic PBC study in a decade? An international study evaluating the farnesoid X receptor agonist obeticholic acid in PBC

R. Chapman, A. Burroughs, D. Shapiro, 2011, Gut.

Time-dependent factors associated with diminished transplant-free survival in patients with primary biliary cholangitis and an optimal response to ursodeoxycholic acid after one year of treatment

F. Nevens, K. Lindor, C. Ponsioen, 2017 .

The GLOBE score identifies PBC patients at increased risk of liver transplantation or death in different age-categories over time

F. Nevens, K. Lindor, C. Ponsioen, 2017 .

The GLOBE score identifies PBC patients at increased risk of liver transplantation or death during follow-up

F. Nevens, K. Lindor, C. Ponsioen, 2016 .

Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’

I. Mackay, R. Gish, David E. J. Jones, 2015, Gut.

Collagen type Ialpha1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis.

F. Rivera, F. Pons, N. Guañabens, 2001, Hepatology.

The novel hexokinase 1 antibodies are useful for the diagnosis and associated with bad prognosis in primary biliary cholangitis

M. Mahler, M. Romera, Z. Shums, 2017 .

Changing Nomenclature for PBC: From 'Cirrhosis' to 'Cholangitis'.

I. Mackay, R. Gish, David E. J. Jones, 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Time‐dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis

Thore Egeland, Annika Bergquist, Giuseppe Rocca, 2002, Hepatology.

[Prevalence and factors associated to the presence of fatty liver in apparently healthy adult men].

R. Tresserras, J. Rodés, J. Caballería, 2000, Medicina clinica.

Effect of parenteral amino acid supplementation on short‐term and long‐term outcomes in severe alcoholic hepatitis: A randomized controlled trial

J. Caballería, H. Herlong, E. Mezey, 1991, Hepatology.

Hyperhomocysteinemia in chronic alcoholism. Relationship to liver damage

J. Rodés, J. Lluis, R. Deulofeu, 2002 .

Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis

R. Deulofeu, J. Caballería, L. Caballería, 1996, Hepatology.

Bone fractures in primary biliary cholangitis

N. Guañabens, A. Parés, 2023, Journal of internal medicine.